Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease☆


Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence demonstrating that the different amyloid PET ligands that are currently available are valid biomarkers for Alzheimer-related β amyloidosis. Based on recent findings from cross-sectional and longitudinal imaging studies using different modalities, we will… (More)
DOI: 10.1016/j.nicl.2013.03.014


6 Figures and Tables

Slides referencing similar topics